Evotec's hybrid CRO approach pays off in Q1

Germany's Evotec splits its operation between contract research for big-name third parties and in-house work on its own pipeline, riding its uncommon take on the CRO business to an uptick in revenue last quarter.

Evotec brought in about $24.1 million in revenue on the quarter, good for about 3% growth. EVT Execute, the company's CRO arm, brought in $26.3 million on the quarter, while EVT Innovate, which outlicenses internal candidates, picked up $3.4 million. However, $5.5 million in intersegment eliminations--in which one business sold services to the other--brought down the revenue total.

The company took a $5.5 million net loss on the quarter, but Evotec considers itself in a strong position with about $124 million in cash and more on the way tied to near-term milestones from its many partnerships.

Last month, Evotec teamed up with Debiopharm and Convergence Pharmaceuticals in separate deals to handle early-stage drug development work, dovetailing with the company's core business of pursuing risk-splitting projects with drug developing sponsors in exchange for CRO fees and a cut of future profits. That model has attracted collaborators including Bayer, Boehringer Ingelheim, Johnson & Johnson ($JNJ) and Roche ($RHHBY).

And the Hamburg-headquartered company is working to expand EVT Innovate, its internal program, in March buying up a biopharma asset management company to bring in a pipeline of its own and get to work on some unpartnered assets.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.